Communiqués Akili, Inc.

Actions

AKLI

US00974B1070

Cours en clôture Nasdaq Autres places de cotation 00:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
0,4206 ^USD	+0,17 %		+0,38 %	-13,65 %

14/05	Akili, Inc. communique ses résultats pour le premier trimestre clos le 31 mars 2024	CI
30/04	Akili, Inc. prévoit de continuer à obtenir l'autorisation de mise sur le marché de la Food and Drug Administration des États-Unis pour son produit EndeavorOTC	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Shareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public Shareholders	29/05	PR
Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company	29/05	BU
Akili Reports First Quarter 2024 Financial Results and Provides Business Update	14/05	BU
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results	30/04	BU
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	29/02	BU
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	28/02	AQ
Shionogi & Co., Ltd. - Positive Results from Phase 3 Clinical trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan	27/02	AQ
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	27/02	AQ
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan	26/02	BU
Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates	21/02	BU
EndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17	18/12	BU
Ubongo Takes Digital Literacy Campaign to Burera	21/11	AQ
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update	09/11	BU
'Black Panther' stuntman Taraja Ramsess, 3 of his children die in car crash	07/11	AQ
Akili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ET	19/10/23	BU
Employees with ADHD Aren't Reaching Their Full Potential at Work, Akili Study Finds	13/10/23	AQ
Employees with ADHD Aren’t Reaching Their Full Potential at Work, Akili Study Finds	12/10/23	BU
Akili Announces Leadership Transition	09/10/23	AQ
Akili Announces Leadership Transition	06/10/23	BU
Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD	21/09/23	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Akili, Inc.

Actions

AKLI

US00974B1070

Communiqués

Filtres